Leerink Partners initiated coverage of Intra-Cellular Therapies (NASDAQ:ITCI) with an “outperform” rating and $27 price target. The stock closed at $15.86 on Nov. 14. Intra-Cellular is focused on development of...

Leerink Partners upgraded Mersana Therapeutics (NASDAQ:MRSN) to “outperform” from “market perform” but maintained its price target of $14, citing the stock’s valuation. It closed at $6.04 on Nov. 13. “We are upgrading...

Leerink Partners launched coverage of Biohaven Pharmaceutical Holding (NYSE:BHVN) with an “outperform” rating and $50 price target. The stock closed at $36.90 on Nov. 13. Biohaven is focused on a range of neurological...

Maxim Group launched coverage of Moleculin Biotech (NASDAQ:MBRX) with a “buy” rating and $3 price target. The stock closed at $1.35 on Nov. 13. Moleculin has three differentiated oncology programs: a STAT3 inhibitor for...

SVB Financial Group (NASDAQ:SIVB), the parent company of Silicon Valley Bank, agreed to acquire Leerink Holdings for $280 million. Leerink is a Boston-based parent company of Leerink Partners, a leading investment bank...

William Blair initiated coverage of LogicBio Therapeutics (NASDAQ:LOGC) with an “outperform” rating and $26 fair value estimate. The stock closed at $15.11 on Nov. 12. LogicBio’s GeneRide platform is a promoter-less...

Maxim Group raised its price target for Matinas BioPharma (NYSE American:MTNB) to $5 from $2 after the American Heart Association meeting over the weekend. The stock closed at $1.11 on Nov. 9. “We are factoring in...

Stifel initiated coverage of Equillium (NASDAQ:EQ) with a “buy” rating and $22 price target. The stock closed at $16.34 on Nov. 5. “Our bullish thesis centers on the potential for lead asset, EQ001, a first-in-class...

Roth Capital Partners upgraded Syros Pharmaceuticals (NASDAQ:SYRS) to “buy” but maintained its $12 price target, citing recent erosion of the company’s market value. The stock closed at $7.76 on Nov. 2 after trading...

Ladenburg Thalmann initiated coverage of Aptevo Therapeutics (NASDAQ:APVO) with a “buy” rating and $14 price target. The stock closed at $3.63 on Nov. 2. Aptevo is developing biotherapeutics for oncology and autoimmune...

H.C. Wainwright downgraded Trevena (NASDAQ:TRVN) to “neutral” from “buy” and slashed its price target to 75 cents from $3 after the company received a complete response letter (CRL) on Nov. 2 from the FDA for...

Leerink lowered its price target for Clovis Oncology (NASDAQ:CLVS) to $22 from $30 but maintained its “market perform” rating after the company reported third quarter results. The stock closed at $16.61 on Oct. 30...

Maxim Group initiated coverage of Adial Pharmaceuticals (NASDAQ:ADIL) with a “buy” rating and $5 price target. The stock closed at $1.88 on Oct. 29. Adial is developing AD04, an ultra-low-dose ondansetron therapy for...

Maxim Group launched coverage of Proteon Therapeutics (NASDAQ:PRTO) with a “buy” rating and a price target of $5. The stock closed at $1.71 on Oct. 29. The company’s vonapanitase drug candidate is being evaluated in its...

William Blair launched coverage of Celyad S.A. (NASDAQ:CYAD) with an “outperform” rating and a fair value estimate of $53. The stock closed at $23.58 on Oct.29. Celyad’s lead candidate, CYAD-01, is an autologous...

H.C. Wainwright initiated coverage of ADMA Biologics (NASDAQ:ADMA) with a “buy” rating and $17 price target. The stock closed at $5.03 on Oct. 29. Since its IPO in 2013, the company’s focus has been on bringing a...

Leerink launched coverage of Inspire Medical Systems (NYSE:INSP) with an “outperform” rating and $57 price target. The stock closed at $40 on Oct. 26. “We see Inspire as a sustainable ultra high-growth/gross margin...

Stifel initiated coverage of IRIDEX (NASDAQ:IRIX) with a “buy” rating and price target of $9. The stock closed at $5.40 on Oct. 25. IRIDEX is a leader in developing, manufacturing, and marketing laser-based medical...

Ladenburg Thalmann launched coverage of Athenex (NASDAQ:ATNX) with a “buy” rating and $27 price target. The stock closed at $12.37 on Oct. 24. Athenex is focused on the development and commercialization of novel...

H.C. Wainwright initiated coverage of Autolus Therapeutics (NASDAQ:AUTL) with a “buy” rating and $45 price target. The stock closed at $30.64 on Oct. 23. Autolus is a UK-based, oncology-focused, autologous cell therapy...